---
document_datetime: 2025-11-23 08:03:50
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ibandronic-acid-hexal.html
document_name: ibandronic-acid-hexal.html
version: success
processing_time: 0.087996
conversion_datetime: 2025-12-27 22:47:42.910832
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ibandronic Acid Hexal

[RSS](/en/individual-human-medicine.xml/67063)

##### Application withdrawn

The application for this medicine has been withdrawn

ibandronic acid

Medicine

Human

Application withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Key facts](#key-facts)
- [All documents](#all-documents)
- [Related information on withdrawals](#related-info-withdrawn)
- [More information on Ibandronic Acid Hexal](#more-information-on-ibandronic-acid-hexal-62349)
- [Related documents](#related-documents-63566)
- [Topics](#topics)

- Application under evaluation
- Withdrawal of application

## Overview

On 21 July 2011, Hexal AG officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Ibandronic Acid Hexal, for the prevention of skeletal events in patients with breast cancer and bone metastases.

Expand section

Collapse section

## What is Ibandronic Acid Hexal?

Ibandronic Acid Hexal is a medicine that contains the active substance ibandronic acid. It was to be available as white tablets.

Ibandronic Acid Hexal was developed as a 'generic medicine'. This means that Ibandronic Acid Hexal was intended to be similar to a 'reference medicine' already authorised in the European Union called Bondronat.

## What was Ibandronic Acid Hexal expected to be used for?

Ibandronic Acid Hexal was to be used to prevent 'skeletal events' (fractures [broken bones] or bone complications requiring treatment) in patients with breast cancer and bone metastases (when the cancer has spread to the bone).

## How is Ibandronic Acid Hexal expected to work?

Ibandronic Acid Hexal is expected to work in the same way as the reference medicine, Bondronat. The active substance in Ibandronic Acid Hexal and Bondronat, ibandronic acid, is a bisphosphonate. It stops the action of the osteoclasts, the cells in the body that are involved in breaking down the bone tissue. This leads to less bone loss. The reduction of bone loss helps to make bones less likely to break, which is useful in preventing fractures in cancer patients with bone metastases.

## What did the company present to support its application?

Because Ibandronic Acid Hexal was developed as a generic medicine, the company presented the results of studies carried out to investigate whether it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## How far into the evaluation was the application when it was withdrawn?

The evaluation had finished and the CHMP had given a positive opinion. The company withdrew before the European Commission had issued a decision on this opinion.

## What was the recommendation of the CHMP at that time?

The CHMP concluded that, in accordance with EU requirements, Ibandronic Acid Hexal had been shown to have comparable quality and to be bioequivalent to Bondronat. Therefore, the CHMP's view was that, as for Bondronat, the benefit outweighs the identified risk. The Committee recommended that Ibandronic Acid Hexal be given marketing authorisation.

## What were the reasons given by the company for withdrawing the application?

The letter from the company notifying the Agency of the withdrawal of the application is available under the tab 'All documents'.

Questions and answers on the withdrawal of the marketing authorisation application for Ibandronic Acid Hexal

Reference Number: EMA/685524/2011

English (EN) (64.09 KB - PDF)

**First published:** 22/08/2011

**Last updated:** 22/08/2011

[View](/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_en.pdf)

[Other languages (21)](#file-language-dropdown-852)

български (BG) (91.28 KB - PDF)

**First published:**

22/08/2011

**Last updated:**

22/08/2011

[View](/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_bg.pdf)

español (ES) (117.97 KB - PDF)

**First published:**

22/08/2011

**Last updated:**

22/08/2011

[View](/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_es.pdf)

čeština (CS) (81.97 KB - PDF)

**First published:**

22/08/2011

**Last updated:**

22/08/2011

[View](/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_cs.pdf)

dansk (DA) (118.57 KB - PDF)

**First published:**

22/08/2011

**Last updated:**

22/08/2011

[View](/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_da.pdf)

Deutsch (DE) (57.28 KB - PDF)

**First published:**

22/08/2011

**Last updated:**

22/08/2011

[View](/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_de.pdf)

eesti keel (ET) (116.76 KB - PDF)

**First published:**

22/08/2011

**Last updated:**

22/08/2011

[View](/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_et.pdf)

ελληνικά (EL) (92.47 KB - PDF)

**First published:**

22/08/2011

**Last updated:**

22/08/2011

[View](/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_el.pdf)

français (FR) (133.57 KB - PDF)

**First published:**

22/08/2011

**Last updated:**

22/08/2011

[View](/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_fr.pdf)

italiano (IT) (132.7 KB - PDF)

**First published:**

22/08/2011

**Last updated:**

22/08/2011

[View](/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_it.pdf)

latviešu valoda (LV) (141.12 KB - PDF)

**First published:**

22/08/2011

**Last updated:**

22/08/2011

[View](/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_lv.pdf)

lietuvių kalba (LT) (81.17 KB - PDF)

**First published:**

22/08/2011

**Last updated:**

22/08/2011

[View](/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_lt.pdf)

magyar (HU) (138.64 KB - PDF)

**First published:**

22/08/2011

**Last updated:**

22/08/2011

[View](/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_hu.pdf)

Malti (MT) (140.52 KB - PDF)

**First published:**

22/08/2011

**Last updated:**

22/08/2011

[View](/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_mt.pdf)

Nederlands (NL) (117.53 KB - PDF)

**First published:**

22/08/2011

**Last updated:**

22/08/2011

[View](/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_nl.pdf)

polski (PL) (141.18 KB - PDF)

**First published:**

22/08/2011

**Last updated:**

22/08/2011

[View](/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_pl.pdf)

português (PT) (56.44 KB - PDF)

**First published:**

22/08/2011

**Last updated:**

22/08/2011

[View](/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_pt.pdf)

română (RO) (80.29 KB - PDF)

**First published:**

22/08/2011

**Last updated:**

22/08/2011

[View](/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_ro.pdf)

slovenčina (SK) (140.94 KB - PDF)

**First published:**

22/08/2011

**Last updated:**

22/08/2011

[View](/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_sk.pdf)

slovenščina (SL) (78.37 KB - PDF)

**First published:**

22/08/2011

**Last updated:**

22/08/2011

[View](/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_sl.pdf)

Suomi (FI) (116.5 KB - PDF)

**First published:**

22/08/2011

**Last updated:**

22/08/2011

[View](/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_fi.pdf)

svenska (SV) (57.66 KB - PDF)

**First published:**

22/08/2011

**Last updated:**

22/08/2011

[View](/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_sv.pdf)

## Key facts

Name of medicine Ibandronic Acid Hexal Active substance ibandronic acid International non-proprietary name (INN) or common name ibandronic acid Therapeutic area (MeSH)

- Hypercalcemia
- Breast Neoplasms
- Osteoporosis
- Neoplasm Metastasis

Anatomical therapeutic chemical (ATC) code M05BA06 EMA product number EMEA/H/C/002366

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation applicant Hexal AG Withdrawal of application 21/07/2011

## All documents

Withdrawal assessment report for Ibandronic Acid Hexal

Adopted

Reference Number: EMA/CHMP/90168/2011

English (EN) (262.56 KB - PDF)

**First published:** 21/10/2011

**Last updated:** 21/10/2011

[View](/en/documents/withdrawal-report/withdrawal-assessment-report-ibandronic-acid-hexal_en.pdf)

Withdrawal letter: Ibandronic Acid Hexal

English (EN) (318.61 KB - PDF)

**First published:** 22/08/2011

**Last updated:** 22/08/2011

[View](/en/documents/withdrawal-letter/withdrawal-letter-ibandronic-acid-hexal_en.pdf)

#### Related information on withdrawals

A question-and-answer (Q&amp;A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

#### More information on Ibandronic Acid Hexal

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-44)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Related documents

Hexal AG withdraws its marketing authorisation application for Ibandronic acid Hexal (ibandronic acid)

Reference Number: EMA/589738/2011

English (EN) (121.37 KB - PDF)

**First published:** 27/07/2011

**Last updated:** 27/07/2011

[View](/en/documents/press-release/hexal-ag-withdraws-its-marketing-authorisation-application-ibandronic-acid-hexal-ibandronic-acid_en.pdf)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 22/08/2011

## Share this page

[Back to top](#main-content)